Magdalena Benetkiewicz

发表

Chromosome 22 array-CGH profiling of breast cancer delimited minimal common regions of genomic imbalances and revealed frequent intra-tumoral genetic heterogeneity.

A. Piotrowski, J. Dumanski, M. Jankowski, 2006, International Journal of Oncology.

Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression

Robin Andersson, Michał Jankowski, David B Allison, 2010, European Journal of Human Genetics.

Identification of limited regions of genetic aberrations in patients affected with Wilms' tumor using a tiling‐path chromosome 22 array

M. Gessler, T. de Ståhl, J. Dumanski, 2006, International journal of cancer.

High-resolution array-CGH profiling of germline and tumor-specific copy number alterations on chromosome 22 in patients affected with schwannomas

Tiit Mathiesen, Arkadiusz Piotrowski, Jan P. Dumanski, 2005, Human Genetics.

A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications.

D. Pinkel, D. Albertson, I. Dunham, 2002, Human molecular genetics.

High-resolution profiling of an 11 Mb segment of human chromosome 22 in sporadic schwannoma using array-CGH.

C. Bruder, J. Dumanski, G. Evans, 2003, International journal of oncology.

Microarray‐based survey of CpG islands identifies concurrent hyper‐ and hypomethylation patterns in tissues derived from patients with breast cancer

Michał Jankowski, Arkadiusz Piotrowski, Uwe Menzel, 2006, Genes, chromosomes & cancer.

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

C. Tournigand, P. Laurent-Puig, F. Bonnetain, 2015, BMC Cancer.

Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review

C. Tournigand, F. Bonnetain, A. de Gramont, 2015, Therapeutic advances in medical oncology.

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

M. Moore, D. Goldstein, D. Vernerey, 2016, British Journal of Cancer.

Biomarker Development in Targeting Cancer Epigenetic

E. Raymond, S. Faivre, A. Gramont, 2016 .

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer

C. Borg, F. Ghiringhelli, Stefano Kim, 2018, World journal of clinical oncology.

Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth.

Olivier Delattre, Birgit Geoerger, D. Surdez, 2012, Cancer research.

NOTCH2 Is Neither Rearranged nor Mutated in t(1;19) Positive Oligodendrogliomas

K. Hoang-Xuan, Y. Marie, M. Sanson, 2009, PloS one.

Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials

T. Hickish, R. Salazar, J. Tabernero, 2019, Cancer Epidemiology, Biomarkers & Prevention.

Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study.

C. Tournigand, A. Larsen, A. de Gramont, 2020, Clinical colorectal cancer.

Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study

M. Housset, S. Albert, F. Chabolle, 2015, Cancer medicine.